<DOC>
	<DOCNO>NCT00111956</DOCNO>
	<brief_summary>Metabolic syndrome associate increase inflammatory cytokine reduce adiponectin , may mediate part TNF production abdominal fat . We reason anti-TNF agent would reduce C-reactive protein ( CRP ) increase adiponectin , improve inflammatory milieu associate metabolic syndrome .</brief_summary>
	<brief_title>Effects Tumor Necrosis Factor ( TNF ) -Alpha Antagonism Patients With Metabolic Syndrome</brief_title>
	<detailed_description>Screening visit 1 : Fifty six patient randomize receive etanercept identical placebo . During screen visit , informed consent obtain , subject undergo medical history physical exam , include vital sign , weight , abdominal girth measurement evaluation sign underlie infection . A purified protein derivative ( PPD ) 5 tuberculin unit ( TU ) ( 0.1 milliliter 5 TU/0.1 ml solution ) intradermally place test presence tuberculosis ( TB ) . Fasting blood work include complete blood count ( CBC ) , glucose , insulin , cholesterol panel , urine pregnancy test . Subjects show subcutaneous injection entail use placebo . Patients select base laboratory result , abdominal girth measurement PPD negativity 48 hr placement . Screening visit 2 : Subjects return 48 hour first screen visit evaluation PPD test . In event positive PPD , subject exclude study , primary care physician notify test result . Day 1 visit : Subjects report Massachusetts General Hospital ( MGH ) Massachusetts Institute Technology ( MIT ) Clinical Research Center ( GCRC ) overnight fast . Fasting blood work obtain test CRP , adiponectin , IL-6 , TNF-alpha , TNF-alpha receptor 1 , TNF-alpha receptor 2 , free fatty acid , glucose , insulin cholesterol panel , CBC . A urine pregnancy test do . Patients ask recall food consume past 24 hour . A bionutritionist measure height , weight , waist , hip , chest , arm , neck thigh circumference . Subjects instructed practice adequate birth control throughout study . Serum store etanercept antibody test . Subjects undergo insulin modify frequently sample intravenous ( IV ) glucose tolerance test ( FSIGT ) initially develop Bergman et al . Dual energy x-ray absorptiometry ( DEXA ) ( Hologic QDR 4500 ) use determine whole body regional fat . The technique precision error ( 1 SD ) 3 % whole body fat 1.5 % lean mass . Subjects also undergo single thin-slice CT scan abdomen L4 vertebral body determine visceral subcutaneous fat area . Indirect calorimetry measurement rest energy expenditure indirect calorimetry use Deltatrac instrument ( Sensormedics , Anaheim , CA ) carry . Drug administration : Patients give total either etanercept 50 mg subcutaneously placebo subcutaneously GCRC end visit . They receive two injection 25 mg , one give immediately follow , different body site . Etanercept supply sterile , white , preservative-free , lyophilized powder . The pharmacy reconstitute 1 mL supply sterile bacteriostatic water injection ( BWFI ) , USP ( contain 0.9 % benzyl alcohol ) . Each vial etanercept contain 25 mg etanercept , 40 mg mannitol , 10 mg sucrose , 1.2 mg tromethamine . Subjects receive 50 mg dose etanercept placebo week , give two 25 mg injection , one immediately follow , different body site , ensue three visit GCRC , Visit Day 8 , Visit Day 15 Visit Day 22 . Subjects monitor 30 minute injection study drug visit . The skin injection site observe vital sign take . If subject significant exposure varicella virus study , transient termination study consider . Day 8 visit , Day 15 visit , Day 22 visit : Subjects report MGH MIT Clinical Research Center overnight fast . Each subject undergo history physical exam ass safety compliance . Fasting blood work obtain . A bionutritionist measure subject ' height , weight , hip waist circumference calculate waist hip ratio . They receive 50 mg either etanercept placebo , give two 25 mg dos subcutaneously , different body site . Day 25 visit : Subjects report MGH MIT Clinical Research Center overnight fast . Each subject undergo history physical exam ass safety compliance . Blood work , urine pregnancy test 24 hour food recall collect , identical Day 1 visit . Anthropomorphic measurement Day 1 visit . Subjects undergo intravenous glucose tolerance test ( IVGTT ) identical Day 1 visit . Subjects undergo DEXA , bioelectric impedance analysis ( BIA ) , CT , indirect calorimetry identical Day 1 visit . No study drug administer visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Hyperinsulinemia upper quartile nondiabetic population define ≥10 mU/mL ( Framingham Data , oral communication , James Meigs , MD ) fast glucose 110126 mg/dL , plus two following : *Abdominal obesity define waist hip ratio &gt; 0.90 men &gt; 0.85 woman *body mass index ( BMI ) &gt; 30 kg/m2 Dyslipidemia include serum triglyceride ≥150 mg/dl serum HDL &lt; 0.9 mmol/L men ( 35 mg/dL ) &lt; 1.0 mmol/L ( 39 mg/dL ) woman Hypertension define blood pressure ≥ 140/90 medication Positive PPD ( ≥ 5mm induration ) screen Current infection Therapy glucocorticoid immunosuppressant time recruitment within past 3 month Reception live vaccine within 1 week recruitment History blood dyscrasia include kind anemia , thrombocytopenia , pancytopenia . Women reversible cause anemia resolve eligible . History malignancy ( except patient surgically cure basal cell squamous cell skin cancer eligible ) History organ transplantation History central nervous system ( CNS ) demyelinate disorder first degree relative multiple sclerosis History congestive heart failure ( CHF ) class IIV Current use insulin , oral antihyperglycemic agent , pentoxyfylline , betaagonists Current use fibrate niacin Initiation statin therapy within prior 6 week expect change statin dose upcoming 3 month Hemoglobin &lt; 11 g/dl Positive pregnancy test Women childbearing potential currently use nonhormonal birth control method include barrier method ( intrauterine device [ IUD ] , condom , diaphragm ) abstinence Patients know autoimmune inflammatory condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>TNF</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>inflammation</keyword>
	<keyword>CRP</keyword>
	<keyword>adiponectin</keyword>
</DOC>